BEDMINSTER, N.J. and DUBLIN, Ireland, July 25, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the development of therapeutics to improve cardiovascular health, announced today that the European Patent Office has issued an intention to grant letter for European Patent Application Number EP2395991, titled “Use of Eicosapentaenoic Acid Ethyl Ester for Treating Hypertriglyceridemia.” This patent application is intended to protect the exclusivity of Amarin’s drug candidate, AMR101, for use in an indication that Amarin may seek through the European Medicines Agency (EMA).
